KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vir Biotechnology (VIR) EPS (Basic) (2018 - 2025)

Vir Biotechnology's EPS (Basic) history spans 8 years, with the latest figure at -$0.3 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 60.53% to -$0.3 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.15, a 17.54% increase, with the full-year FY2025 number at -$3.16, up 17.49% from a year prior.
  • EPS (Basic) hit -$0.3 in Q4 2025 for Vir Biotechnology, up from -$1.17 in the prior quarter.
  • Over the last five years, EPS (Basic) for VIR hit a ceiling of $4.04 in Q4 2021 and a floor of -$1.56 in Q3 2024.
  • Historically, EPS (Basic) has averaged -$0.18 across 5 years, with a median of -$0.78 in 2022.
  • Biggest five-year swings in EPS (Basic): soared 586.75% in 2021 and later tumbled 220.83% in 2022.
  • Tracing VIR's EPS (Basic) over 5 years: stood at $4.04 in 2021, then tumbled by 119.06% to -$0.77 in 2022, then fell by 11.69% to -$0.86 in 2023, then rose by 11.63% to -$0.76 in 2024, then soared by 60.53% to -$0.3 in 2025.
  • Business Quant data shows EPS (Basic) for VIR at -$0.3 in Q4 2025, -$1.17 in Q3 2025, and -$0.8 in Q2 2025.